8 Sources of evidence considered by the Committee

A. The Evidence Review Group (ERG) report for this appraisal was prepared by Aberdeen HTA Group:

Cummins E, Scott N, Cruickshank M et al., Secukinumab for treating moderate to severe plaque psoriasis, February 2015

B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope. Organisations listed in I were also invited to make written submissions. Organisations listed in II gave their expert views. Organisations listed in I, II and III have the opportunity to appeal against the final appraisal determination.

I. Company:

Novartis

II. Professional/expert and patient/carer groups:

British Association of Dermatologists
British Dermatological Nursing Group
Psoriasis Association
Psoriasis and Psoriatic Arthritis Alliance
Royal College of Physicians

III. Other consultees:

Department of Health
NHS England
Welsh Government

IV. Commentator organisations (did not provide written evidence and without the right of appeal):

AbbVie
Department of Health, Social Services and Public Safety for Northern Ireland
Healthcare Improvement Scotland
Janssen
Merck Sharp & Dohme
Pfizer

C. The following individuals were selected from clinical expert and patient expert nominations from the consultees and commentators. They gave their expert personal view on secukinumab by providing oral evidence to the Committee.

Dr Ruth Murphy, nominated by British Association of Dermatologists – clinical expert
Professor Catherine Smith, nominated by British Association of Dermatologists – clinical expert
Lucy Moorhead, nominated by British Dermatological Nursing Group – clinical expert
David Chandler, nominated by Psoriasis and Psoriatic Arthritis Alliance – patient expert

D. Representatives from the following company attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

Novartis